Back to results
US 8,710,004 B2Granted
Stable liquid VEGF antagonist formulations
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsDaniel Dix, Kelly Frye, Susan Kautz
Life of this patent
Estimating the term…
Abstract
Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
Claims6
A stable liquid formulation of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist, comprising 10-100 mg/ml of a fusion protein comprising amino acids 27-457 of SEQ ID NO:
- 4;
- 5 mM phosphate and 5 mM citrate, at a pH of about 6.0-6.5;
- about 20% sucrose;
- about 50-100 mM NaCl;
- and about 0.1% polysorbate 20.
2 more elements
Dependencies are inferred from the claim text.